Cargando…

Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer

Precise diagnosis of early prostate cancer (PCa) is critical for preventing tumor progression. However, the diagnostic outcomes of currently used markers are far from satisfactory due to the low sensitivity or specificity. Here, we identified a diagnostic subpopulation in PCa tissue with the integra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiaoshi, Chen, Lipeng, Chen, Tao, Chen, Kun, Zhang, Huirong, Huang, Kaipeng, Zheng, Han, Jin, Hongtao, Cheng, Zhiqiang, Xiao, Kefeng, Guo, Jinan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663703/
https://www.ncbi.nlm.nih.gov/pubmed/38022698
http://dx.doi.org/10.1016/j.csbj.2023.10.044
_version_ 1785138457905987584
author Ma, Xiaoshi
Chen, Lipeng
Chen, Tao
Chen, Kun
Zhang, Huirong
Huang, Kaipeng
Zheng, Han
Jin, Hongtao
Cheng, Zhiqiang
Xiao, Kefeng
Guo, Jinan
author_facet Ma, Xiaoshi
Chen, Lipeng
Chen, Tao
Chen, Kun
Zhang, Huirong
Huang, Kaipeng
Zheng, Han
Jin, Hongtao
Cheng, Zhiqiang
Xiao, Kefeng
Guo, Jinan
author_sort Ma, Xiaoshi
collection PubMed
description Precise diagnosis of early prostate cancer (PCa) is critical for preventing tumor progression. However, the diagnostic outcomes of currently used markers are far from satisfactory due to the low sensitivity or specificity. Here, we identified a diagnostic subpopulation in PCa tissue with the integrating analysis of single-cell and bulk RNA-seq. The representative markers of this subpopulation were extracted to perform intersection analysis with early-PCa-related gene module generated from weighted correlation network analysis (WGCNA). A total of 24 overlapping genes were obtained, the diagnostic roles of which were validated by distinguishing normal and tumorous prostate samples from the public dataset. A least absolute shrinkage and selection operator (LASSO) model was constructed based on these genes and the obtained 24-gene panel showed high sensitivity and specificity for PCa diagnosis, with better identifying capability of PCa than the commercially used gene panel of Oncotype DX. The top two risk factors, TRPM4 and PODXL2, were verified to be highly expressed in early PCa tissues by multiplex immunostaining, and PODXL2 was more sensitive and specific compared to TRPM4 and the pathologically used marker AMACR for early PCa diagnosis, suggesting a novel and promising pathology marker.
format Online
Article
Text
id pubmed-10663703
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-106637032023-10-26 Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer Ma, Xiaoshi Chen, Lipeng Chen, Tao Chen, Kun Zhang, Huirong Huang, Kaipeng Zheng, Han Jin, Hongtao Cheng, Zhiqiang Xiao, Kefeng Guo, Jinan Comput Struct Biotechnol J Research Article Precise diagnosis of early prostate cancer (PCa) is critical for preventing tumor progression. However, the diagnostic outcomes of currently used markers are far from satisfactory due to the low sensitivity or specificity. Here, we identified a diagnostic subpopulation in PCa tissue with the integrating analysis of single-cell and bulk RNA-seq. The representative markers of this subpopulation were extracted to perform intersection analysis with early-PCa-related gene module generated from weighted correlation network analysis (WGCNA). A total of 24 overlapping genes were obtained, the diagnostic roles of which were validated by distinguishing normal and tumorous prostate samples from the public dataset. A least absolute shrinkage and selection operator (LASSO) model was constructed based on these genes and the obtained 24-gene panel showed high sensitivity and specificity for PCa diagnosis, with better identifying capability of PCa than the commercially used gene panel of Oncotype DX. The top two risk factors, TRPM4 and PODXL2, were verified to be highly expressed in early PCa tissues by multiplex immunostaining, and PODXL2 was more sensitive and specific compared to TRPM4 and the pathologically used marker AMACR for early PCa diagnosis, suggesting a novel and promising pathology marker. Research Network of Computational and Structural Biotechnology 2023-10-26 /pmc/articles/PMC10663703/ /pubmed/38022698 http://dx.doi.org/10.1016/j.csbj.2023.10.044 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Ma, Xiaoshi
Chen, Lipeng
Chen, Tao
Chen, Kun
Zhang, Huirong
Huang, Kaipeng
Zheng, Han
Jin, Hongtao
Cheng, Zhiqiang
Xiao, Kefeng
Guo, Jinan
Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer
title Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer
title_full Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer
title_fullStr Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer
title_full_unstemmed Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer
title_short Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer
title_sort identification of a 24-gene panel and a novel marker of podxl2 essential for the pathological diagnosis of early prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663703/
https://www.ncbi.nlm.nih.gov/pubmed/38022698
http://dx.doi.org/10.1016/j.csbj.2023.10.044
work_keys_str_mv AT maxiaoshi identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT chenlipeng identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT chentao identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT chenkun identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT zhanghuirong identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT huangkaipeng identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT zhenghan identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT jinhongtao identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT chengzhiqiang identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT xiaokefeng identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer
AT guojinan identificationofa24genepanelandanovelmarkerofpodxl2essentialforthepathologicaldiagnosisofearlyprostatecancer